The US FDA conducted an unannounced inspection of Caplin Steriles' injectable and ophthalmic manufacturing facility located at Gummidipoondi between August 13, 2026, and August 21, 2026. The inspection concluded with 10 observations that were described as procedural in nature.

The company received communication of the OAI classification from the US FDA on November 16, 2026.

According to the disclosure, the company does not expect any material impact on its financials or operations as of the date of this intimation (November 17, 2026). The facility continues to manufacture and supply products, and the company remains committed to maintaining the highest standards of quality, current Good Manufacturing Practices (cGMP), and regulatory compliance.

The company has stated its commitment to working closely with the FDA to address the observations and demonstrate the effectiveness and sustainability of corrective and preventive actions.

The annexure to the disclosure provides specific details:

  • Name of authority: US Food and Drug Administration (US FDA), USA
  • Nature of action: US FDA inspection of Caplin Steriles' injectable and ophthalmic manufacturing facility at Gummidipoondi from August 13-21, 2026, concluding with 10 procedural observations
  • Date of receipt of communication: November 16, 2026
  • Details of violation: US FDA determined inspection classification as "Official Action Indicated" (OAI)
  • Financial impact: No material impact on the Company's financials or operations due to the said action

The disclosure was signed by Venkatram Ganapathisubramanian, General Counsel & Company Secretary (Membership No A23989) of Caplin Point Laboratories Limited, and digitally signed on November 17, 2026, at 13:47:26 +05:30.